Editorial: Follistatin-344 Is Mostly a Story We Tell Ourselves
Belgian Blue cattle photos are not human trial data. Follistatin-344 has no controlled human evidence for muscle gain, and the gap matters.
14 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 14 of 14 clinical reviews.
Belgian Blue cattle photos are not human trial data. Follistatin-344 has no controlled human evidence for muscle gain, and the gap matters.
Follistatin-344 grows muscle dramatically in mice and cell models. Human clinical trial data on follistatin-344 for muscle growth does not exist. Here is the actual evidence map.
Follistatin trials used AAV gene therapy in Becker MD and IBM patients, not injectable peptide vials. Here is what the published data actually shows.
No validated human dosing for Follistatin-344 exists. Vendor protocols are unsourced extrapolations, not evidence. Here is what the data actually shows.
Follistatin-344 blocks activin signaling, which also governs fertility, fibrosis, and bone remodeling. Human safety data for this compounded peptide are absent.
Follistatin-344 is named for a precursor length, not the FST315 form that actually circulates in human serum. The splice variant biology, explained plainly.
Creatine has hundreds of human trials and a safety record; Follistatin-344 has none in humans. Here is what that gap actually means for you.
Follistatin-344 has no FDA-approved use, is not on the 503A bulks list, and lacks human clinical trial evidence for any claimed benefit.
Exercise and weight loss change circulating follistatin and FSTL1 in trials, but no study measured the injectable peptide Follistatin-344 itself.
Follistatin-344 blocks myostatin by structural binding, but the same domain also binds activin non-selectively, which is the real safety question.
Follistatin-344 is a folded protein, not a simple peptide chain, which makes counterfeit and degraded vials far harder to detect than with small peptides.
Follistatin-344 sits outside every legitimate myostatin-inhibitor track: not FDA-approved, not on the 503A bulks list, and untested in humans.
Follistatin-344 prices vary widely because of protein synthesis cost, purity claims, and zero regulatory price anchoring, not proven potency differences.
Follistatin-344 is a myostatin-binding splice variant studied mainly in gene-therapy models; no FDA approval or human injectable safety data exist.